文献速递血脂与心血管预防

Inclisiran在青少年纯合子家族性高胆固醇血症中的疗效与安全性:ORION-13随机试验双盲安慰剂对照部分结果

Efficacy and Safety of Inclisiran in Adolescents With Genetically Confirmed Homozygous Familial Hypercholesterolemia: Results From the Double-Blind, Placebo-Controlled Part of the ORION-13 Randomized Trial.
PubMed 文献 · Circulation · 2025-05-20

ORION-13 3期试验双盲安慰剂对照部分纳入13例12至<18岁基因确诊的纯合子家族性高胆固醇血症青少年(排除LDLR null/null基因型),随机2:1接受inclisiran 300 mg或安慰剂(第1、90、270天给药)。第330天LDL-C相对基线安慰剂校正后平均百分比变化为-33.3%(95%CI -59.2%至-7.3%),inclisiran耐受良好,无严重不良事件。

要点

  • Inclisiran在HoFH青少年中降低LDL-C,第330天安慰剂校正后变化-33.3%。
  • 9例inclisiran治疗者中6例LDL-C降低>15%,5例降低>20%。
  • 无严重不良事件、因不良事件停药或死亡,未报告新安全性发现。

核心结论

  • 为期1年的随机对照研究(ORION-13第1部分)显示,inclisiran可有效降低HoFH青少年的LDL-C且耐受良好。
  • 结果支持inclisiran作为具有最低LDLR残余活性HoFH青少年患者的潜在附加治疗。

研究设计与样本

  • 3期多中心研究ORION-13的双盲、安慰剂对照部分,为期1年。
  • 纳入13例≥12至<18岁基因确诊HoFH(排除LDLR null/null基因型)且最大耐受他汀治疗下LDL-C>130 mg/dL的青少年。
  • 患者按2:1随机接受inclisiran sodium 300 mg或安慰剂,第1、90、270天给药。
  • 主要终点为基线至第330天LDL-C平均百分比变化。

主要发现

  • 患者平均年龄14.8岁,平均基线LDL-C为272 mg/dL。
  • 第330天LDL-C相对基线安慰剂校正后平均(95%CI)百分比变化为-33.3%(-59.2%至-7.3%)。
  • 9例inclisiran治疗者中6例(66.7%)LDL-C降低>15%,安慰剂组4例中1例(25%)。
  • 9例inclisiran治疗者中5例(55.6%)LDL-C降低>20%,安慰剂组无。
  • 第330天PCSK9相对基线安慰剂校正后平均(95%CI)百分比变化为-60.2%(-79.8%至-40.7%)。

关键数值与推荐

  • 主要终点第330天LDL-C安慰剂校正后平均百分比变化-33.3%(95%CI -59.2%至-7.3%)。
  • LDL-C降低>15%的比例:inclisiran组66.7%(6/9) vs 安慰剂组25%(1/4)。
  • LDL-C降低>20%的比例:inclisiran组55.6%(5/9) vs 安慰剂组0%。
  • PCSK9安慰剂校正后平均百分比变化-60.2%(95%CI -79.8%至-40.7%)。

临床怎么用

  • 对于最大耐受他汀治疗后LDL-C仍>130 mg/dL且具有LDLR残余活性的HoFH青少年,inclisiran可作为潜在附加治疗选择。
  • 使用inclisiran时需注意其适用人群为排除LDLR null/null基因型的HoFH青少年。

局限性

  • 研究样本量小(共13例),双盲安慰剂对照部分仅1年。
  • 排除LDLR null/null基因型患者,结果不能外推至该亚组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Homozygous familial hypercholesterolemia (HoFH) is a genetic disease characterized by high levels of low-density lipoprotein cholesterol (LDL-C) present from birth, leading to early-onset and progressive atherosclerotic cardiovascular disease. Early treatment initiation is crucial for cardiovascular risk reduction; however, many patients do not reach LDL-C treatment goals. Inclisiran, a small interfering RNA targeting hepatic PCSK9 (proprotein convertase subtilisin/kexin type 9), is effective and well tolerated in adult patients with hyperlipidemia; however, it has not yet been studied in pediatric patients. METHODS: Herein we report results of the 1-year, double-blind, placebo-controlled part of the phase 3 study ORION-13 (Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Homozygous Familial Hypercholesterolemia) in adolescents with HoFH. This 2-part multicenter study included 13 patients ≥12 to <18 years of age with a genetic diagnosis of HoFH (excluding LDL [low-density lipoprotein] receptor [LDLR] null/null genotypes) and elevated LDL-C levels (>130 mg/dL) on maximally tolerated statin treatment, with or without other lipid-lowering therapies. Eligible patients were randomized 2:1 to receive either 300 mg of inclisiran sodium or placebo, administered on days 1, 90, and 270. The primary end point was the mean percentage change in LDL-C from baseline to day 330. RESULTS: The mean age of patients was 14.8 years, and mean baseline LDL-C was 272 mg/dL. The placebo-adjusted mean (95% CI) percentage change in LDL-C from baseline to day 330 was -33.3% (-59.2% to -7.3%). Six of 9 (66.7%) inclisiran-treated patients (versus 1 of 4 [25%] on placebo) achieved a >15% reduction in LDL-C, and 5 of 9 (55.6%) inclisiran-treated patients (versus none on placebo) achieved a >20% reduction. The placebo-adjusted mean (95% CI) percentage change in PCSK9 from baseline to day 330 was -60.2% (-79.8% to -40.7%); corresponding changes in apolipoprotein B, non-high-density lipoprotein cholesterol, and total cholesterol were -23.0%, -32.7%, and -27.8%, respectively. No serious adverse events, treatment discontinuations because of adverse events, or deaths occurred. No new safety findings were reported. CONCLUSIONS: In a 1-year randomized controlled study (part 1 of ORION-13), inclisiran was effective in lowering LDL-C in adolescents with HoFH and was well tolerated. These results support inclisiran as a potentially useful addition for the treatment of adolescents with HoFH and a minimum of LDLR residual activity. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04659863.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Wiegman A, Peterson AL, Hegele RA, et al. Efficacy and Safety of Inclisiran in Adolescents With Genetically Confirmed Homozygous Familial Hypercholesterolemia: Results From the Double-Blind, Placebo-Controlled Part of the ORION-13 Randomized Trial. Circulation. 2025. PMID: 40391436. doi:10.1161/CIRCULATIONAHA.124.073233

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。